Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NLS Pharmaceutics stock | $3.45

Learn how to easily invest in NLS Pharmaceutics stock.

NLS Pharmaceutics AG
NASDAQ: NLSP - USD
BIOTECHNOLOGY
$2.60
-$0.04 (-1.52%)

NLS Pharmaceutics AG is a biotechnology business based in the US. NLS Pharmaceutics shares (NLSP) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in NLS Pharmaceutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NLSP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

NLS Pharmaceutics stock price (NASDAQ: NLSP)

Use our graph to track the performance of NLSP stocks over time.

NLS Pharmaceutics shares at a glance

Information last updated 2021-07-28.
Latest market close$3.45
52-week range$2.06 - $4.70
50-day moving average $3.12
200-day moving average $3.33
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy NLS Pharmaceutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NLS Pharmaceutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NLS Pharmaceutics price performance over time

Historical closes compared with the close of $3.45 from 2021-05-28

1 week (2021-07-21) N/A
1 month (2021-07-01) 10.22%
3 months (2021-04-30) -5.74%
6 months (2021-01-28) N/A
1 year (2020-07-28) N/A
2 years (2019-07-28) N/A
3 years (2018-07-28) N/A
5 years (2016-07-28) N/A

NLS Pharmaceutics financials

Gross profit TTM $0
Return on assets TTM -150.64%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation $33.1 million

TTM: trailing 12 months

Shorting NLS Pharmaceutics shares

There are currently 51,834 NLS Pharmaceutics shares held short by investors – that's known as NLS Pharmaceutics's "short interest". This figure is 37.8% up from 37,610 last month.

There are a few different ways that this level of interest in shorting NLS Pharmaceutics shares can be evaluated.

NLS Pharmaceutics's "short interest ratio" (SIR)

NLS Pharmaceutics's "short interest ratio" (SIR) is the quantity of NLS Pharmaceutics shares currently shorted divided by the average quantity of NLS Pharmaceutics shares traded daily (recently around 647925). NLS Pharmaceutics's SIR currently stands at 0.08. In other words for every 100,000 NLS Pharmaceutics shares traded daily on the market, roughly 80 shares are currently held short.

To gain some more context, you can compare NLS Pharmaceutics's short interest ratio against those of similar companies.

However NLS Pharmaceutics's short interest can also be evaluated against the total number of NLS Pharmaceutics shares, or, against the total number of tradable NLS Pharmaceutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NLS Pharmaceutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 NLS Pharmaceutics shares in existence, roughly 0 shares are currently held short) or 0.0086% of the tradable shares (for every 100,000 tradable NLS Pharmaceutics shares, roughly 9 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NLS Pharmaceutics.

Find out more about how you can short NLS Pharmaceutics stock.

NLS Pharmaceutics share dividends

We're not expecting NLS Pharmaceutics to pay a dividend over the next 12 months.

You may also wish to consider:

NLS Pharmaceutics overview

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland. .

Stocks similar to NLS Pharmaceutics

Frequently asked questions

What percentage of NLS Pharmaceutics is owned by institutions?
Currently 0.629% of NLS Pharmaceutics shares are held by institutions.
When does the fiscal year end for NLS Pharmaceutics?
NLS Pharmaceutics's fiscal year ends in December.
Where is NLS Pharmaceutics based?
NLS Pharmaceutics's address is: Alter Postplatz 2, Stans, Switzerland, 6370

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site